💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Sun Pharma Advanced Research Company Limited is an India-based clinical-stage biopharmaceutical company that focuses on developing therapeutics to improve standards of care for patients worldwide. The Company’s therapeutic focus is in the area of oncology, neurology and…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent business — but flagged on governance.
Sun Pharma Advanced Research is scored on the general / industrial framework. It keeps a fat 82.2% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT -0.15×) — worth a closer look. Free cash flow is worth about -4.2% of its market value.
Book value itself has compounded 38%/yr — the hallmark of a genuine compounder. Return on equity is an elite 113.4%. In the latest quarter profit fell 101% versus the prior quarter.
It trades at 4× earnings. Today's price asks for only ~-15%/yr growth over a decade — undemanding expectations. The forensic screen raises a red flag: Only ₹-1.83 of cash per ₹1 profit over 4 years — earnings not converting to cash.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 3.84 | 2.68 | worse |
| P/B | 4.35 | 2.07 | worse |
| EV/EBITDA | 3.17 | — | — |
| ROE | 113.43 | — | — |
| ROCE | 112.36 | — | — |
| ROA | 97.74 | — | — |
| Quick Ratio | 2.47 | 13.6 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
96% CAGR over 3 years — high-growth territory. Growth is accelerating — latest year outpaced the prior year's rate.
3 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a +553% swing — check if it's a one-off or structural.
Operating margin has expanded from -89% to 82% — the business is keeping more of each rupee earned.
ROE at 116% — the business earns well above its cost of equity. ROE powered by fat margins — the hallmark of a high-quality franchise with pricing power. Capital efficiency improving — ROE up 159pp across the window.
4 of 4 years had negative operating cash flow — profitability on paper may not translate to cash.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 97% QoQ — could be seasonality or a genuine slowdown. Wide quarterly swings (100% spread) — likely seasonality, lumpy orders, or project-based revenue. Run-rate stepping up — recent quarters average 11656% above earlier ones.
3 of 4 quarters loss-making — quarterly profitability is uneven. Profit fell 101% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly net margins are expanding (-964% → -33%) — profitability per rupee of revenue is improving.
P/E band unavailable — needs 5y of consistent EPS + price history.
Promoters hold 65.7% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.